vs
Pacira BioSciences, Inc.（PCRX）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Proto Labs Inc的1.3倍（$177.4M vs $139.3M），Proto Labs Inc净利率更高（5.8% vs 1.6%，领先4.2%），Proto Labs Inc同比增速更快（10.4% vs 5.0%），过去两年Proto Labs Inc的营收复合增速更高（5.3% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
PCRX vs PRLB — 直观对比
营收规模更大
PCRX
是对方的1.3倍
$139.3M
营收增速更快
PRLB
高出5.4%
5.0%
净利率更高
PRLB
高出4.2%
1.6%
两年增速更快
PRLB
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $139.3M |
| 净利润 | $2.9M | $8.1M |
| 毛利率 | — | 45.6% |
| 营业利润率 | 3.9% | 7.1% |
| 净利率 | 1.6% | 5.8% |
| 营收同比 | 5.0% | 10.4% |
| 净利润同比 | — | 125.4% |
| 每股收益（稀释后） | $0.07 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXPRLB
| Q1 26 | $177.4M | $139.3M | ||
| Q4 25 | $196.9M | $136.5M | ||
| Q3 25 | $179.5M | $135.4M | ||
| Q2 25 | $181.1M | $135.1M | ||
| Q1 25 | $168.9M | $126.2M | ||
| Q4 24 | $187.3M | $121.8M | ||
| Q3 24 | $168.6M | $125.6M | ||
| Q2 24 | $178.0M | $125.6M |
净利润PCRXPRLB
| Q1 26 | $2.9M | $8.1M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $7.2M | ||
| Q2 25 | $-4.8M | $4.4M | ||
| Q1 25 | $4.8M | $3.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $7.2M | ||
| Q2 24 | $18.9M | $4.5M |
毛利率PCRXPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | 79.5% | 44.2% | ||
| Q3 25 | 80.9% | 45.3% | ||
| Q2 25 | 77.4% | 44.3% | ||
| Q1 25 | 79.7% | 44.1% | ||
| Q4 24 | 78.7% | 42.7% | ||
| Q3 24 | 76.9% | 45.6% | ||
| Q2 24 | 75.1% | 45.0% |
营业利润率PCRXPRLB
| Q1 26 | 3.9% | 7.1% | ||
| Q4 25 | 1.2% | 5.0% | ||
| Q3 25 | 3.5% | 6.5% | ||
| Q2 25 | 4.7% | 3.7% | ||
| Q1 25 | 1.2% | 3.6% | ||
| Q4 24 | 13.2% | -1.2% | ||
| Q3 24 | -82.8% | 6.8% | ||
| Q2 24 | 15.9% | 4.8% |
净利率PCRXPRLB
| Q1 26 | 1.6% | 5.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 5.3% | ||
| Q2 25 | -2.7% | 3.3% | ||
| Q1 25 | 2.8% | 2.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 5.7% | ||
| Q2 24 | 10.6% | 3.6% |
每股收益（稀释后）PCRXPRLB
| Q1 26 | $0.07 | $0.29 | ||
| Q4 25 | $0.05 | $0.25 | ||
| Q3 25 | $0.12 | $0.30 | ||
| Q2 25 | $-0.11 | $0.18 | ||
| Q1 25 | $0.10 | $0.15 | ||
| Q4 24 | $0.38 | $-0.01 | ||
| Q3 24 | $-3.11 | $0.29 | ||
| Q2 24 | $0.39 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $124.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $683.1M |
| 总资产 | $1.2B | $778.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXPRLB
| Q1 26 | $144.3M | $124.0M | ||
| Q4 25 | $238.4M | $128.1M | ||
| Q3 25 | $246.3M | $119.2M | ||
| Q2 25 | $445.9M | $103.2M | ||
| Q1 25 | $493.6M | $96.8M | ||
| Q4 24 | $484.6M | $103.1M | ||
| Q3 24 | $453.8M | $100.5M | ||
| Q2 24 | $404.2M | $112.9M |
总债务PCRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXPRLB
| Q1 26 | $653.9M | $683.1M | ||
| Q4 25 | $693.1M | $673.9M | ||
| Q3 25 | $727.2M | $664.7M | ||
| Q2 25 | $757.8M | $664.7M | ||
| Q1 25 | $798.5M | $656.8M | ||
| Q4 24 | $778.3M | $670.2M | ||
| Q3 24 | $749.6M | $680.0M | ||
| Q2 24 | $879.3M | $685.2M |
总资产PCRXPRLB
| Q1 26 | $1.2B | $778.6M | ||
| Q4 25 | $1.3B | $763.4M | ||
| Q3 25 | $1.3B | $756.9M | ||
| Q2 25 | $1.5B | $743.3M | ||
| Q1 25 | $1.6B | $737.5M | ||
| Q4 24 | $1.6B | $743.5M | ||
| Q3 24 | $1.5B | $753.8M | ||
| Q2 24 | $1.6B | $758.2M |
负债/权益比PCRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $17.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PCRXPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $43.7M | $16.5M | ||
| Q3 25 | $60.8M | $29.1M | ||
| Q2 25 | $12.0M | $10.6M | ||
| Q1 25 | $35.5M | $18.4M | ||
| Q4 24 | $33.1M | $17.3M | ||
| Q3 24 | $53.9M | $24.8M | ||
| Q2 24 | $53.2M | $14.4M |
自由现金流PCRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $8.4M | ||
| Q3 25 | $57.0M | $25.0M | ||
| Q2 25 | $9.3M | $9.1M | ||
| Q1 25 | $26.9M | $17.1M | ||
| Q4 24 | $31.0M | $16.5M | ||
| Q3 24 | $49.8M | $23.2M | ||
| Q2 24 | $51.6M | $10.2M |
自由现金流率PCRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 6.2% | ||
| Q3 25 | 31.7% | 18.5% | ||
| Q2 25 | 5.1% | 6.7% | ||
| Q1 25 | 15.9% | 13.6% | ||
| Q4 24 | 16.6% | 13.5% | ||
| Q3 24 | 29.6% | 18.5% | ||
| Q2 24 | 29.0% | 8.2% |
资本支出强度PCRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 5.9% | ||
| Q3 25 | 2.2% | 3.0% | ||
| Q2 25 | 1.5% | 1.1% | ||
| Q1 25 | 5.1% | 1.0% | ||
| Q4 24 | 1.1% | 0.7% | ||
| Q3 24 | 2.4% | 1.2% | ||
| Q2 24 | 0.9% | 3.3% |
现金转化率PCRXPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 4.03× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | 7.37× | 5.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | 2.82× | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
